Skip to content
    Real-World Studies

    First-Line Maintenance Niraparib in Advanced Ovarian Cancer

    Fagotti et alESMO Real-World Data and Digital Oncology

    The noninterventional, retrospective European EUROPA study evaluated real-world outcomes associated with first-line maintenance niraparib monotherapy in patients with advanced epithelial ovarian cancer (EOC), specifically examining a clinical subgroup excluded from the pivotal phase III PRIMA trial: patients with stage III disease and no visible residual disease (NVRD) following primary cytoreductive surgery (PCS).
    The study analyzed 186 patients with stage III or IV EOC who initiated first-line maintenance niraparib monotherapy between October 1, 2018, and March 31, 2023, across clinical centers in France, Germany, and Italy. Within this cohort, 48 patients met the criteria for the stage III NVRD subgroup. Investigators assessed real-world progression-free survival (rwPFS) and real-world time to treatment discontinuation (rwTTD).
    In the overall cohort of 186 patients, the median rwTTD was 10.6 months (95% CI: 7.8–18.6), whereas patients in the stage III NVRD subgroup achieved a median rwTTD of 26.2 months (95% CI: 8.9–not reached). Similarly, median rwPFS was 14.7 months (95% CI: 10.1–29.3) in the broader cohort but was not reached among patients with stage III disease and NVRD after PCS. Probabilities for both rwTTD and rwPFS remained consistently higher in the stage III NVRD subgroup relative to the overall cohort at landmark time points of 12, 24, and 36 months after initiation.
    These findings indicate that patients with stage III advanced EOC achieving complete gross resection via PCS derive clinically meaningful real-world benefit from first-line maintenance niraparib, demonstrating descriptively superior survival and treatment retention compared with the broader advanced EOC population.

    Key Takeaways

    • Median real-world progression-free survival was 14.7 months (95% CI: 10.1–29.3) in the overall advanced epithelial ovarian cancer cohort and was not reached in the subgroup with stage III disease and no visible residual disease after primary cytoreductive surgery.
    • Median real-world time to treatment discontinuation was 26.2 months (95% CI: 8.9–not reached) in the stage III no visible residual disease subgroup compared with 10.6 months (95% CI: 7.8–18.6) in the overall cohort.
    • Patients in the stage III no visible residual disease subgroup demonstrated higher real-world progression-free survival and treatment discontinuation probabilities at 12, 24, and 36 months post-index compared to the overall advanced disease cohort.
    Read the original sourceESMO Real-World Data and Digital Oncology